Product Description
BMS-986012 is a first-in-class, fully human mAb with enhanced antibody-dependent cell-mediated cytotoxicity that binds to fucosyl-GM1, a ganglioside highly expressed on SCLC. BMS-986012 monotherapy is well tolerated and has shown evidence of antitumor activity in some pts with rel/ref SCLC in a phase 1/2 study (Sourced from: https://www.annalsofoncology.org/article/S0923-7534(20)38713-5/fulltext)
Mechanisms of Action: FucGM1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Greece, India, Italy, Japan, Korea, Netherlands, Poland, Romania, Spain, Switzerland, Turkey, United Kingdom, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Bristol-Myers Squibb presented P2 Small Cell Lung Cancer results on 2024-09-13 for Atigotatug
Highest Development Phases
Phase 3: Small Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04702880 |
CA001-050 | P2 |
Active, not recruiting |
Small Cell Lung Cancer |
2025-12-31 |
12% |
2024-11-27 |
Primary Endpoints|Treatments |
2024-510700-36-00 |
CA001-050 | P2 |
Active, not recruiting |
Small Cell Lung Cancer |
2026-12-15 |
2025-05-02 |
Treatments |
|
jRCT2051210111 |
jRCT2051210111 | P2 |
Active, not recruiting |
Small Cell Lung Cancer |
2025-03-17 |
|||
2024-511824-15-00 |
CA001-044 | P2 |
Completed |
Small Cell Lung Cancer |
2024-08-06 |
2025-05-02 |
Treatments |
|
2016-001692-67 |
2016-001692-67 | P2 |
Active, not recruiting |
Small Cell Lung Cancer |
2019-07-26 |
21% |
2025-05-17 |
Treatments |
2024-515740-23-00 |
CA245-0001 | P3 |
Recruiting |
Small Cell Lung Cancer |
2031-08-31 |
2025-05-02 |
Treatments |
|
NCT06646276 |
TIGOS | P3 |
Recruiting |
Small Cell Lung Cancer |
2028-04-06 |
50% |
2025-01-31 |
Primary Endpoints|Treatments|Trial Status |